Identification and quantification of nicotine biomarkers in human oral fluid from individuals receiving low-dose transdermal nicotine: A preliminary study

Journal of Analytical Toxicology

Volumn 34, Issue 7, 2010, Pages 357-366

  Miller, Eleanor I ^a   Norris, Hye Ryun K ^a   Rollins, Douglas E ^a   Tiffany, Stephen T ^b   Moore, Christine M ^c   Vincent, Michael J ^c   Agrawal, Alpana ^c   Wilkins, Diana G ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c Immunalysis Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYCOTININE; ANABASINE; ANATABINE; COTININE; COTININE N BETA DEXTRO GLUCURONIDE; COTININE N OXIDE; N BETA DEXTRO GLUCURONIDE; NICOTINE DERIVATIVE; NICOTINE N' OXIDE; NORCOTININE; NORNICOTINE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; NICOTINE; NICOTINIC AGENT;

ANALYTICAL EQUIPMENT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; SALIVA; SALIVA ANALYSIS; SALIVA LEVEL; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; CHEMISTRY; INTRADERMAL DRUG ADMINISTRATION; METHODOLOGY; REPRODUCIBILITY; SOLID PHASE EXTRACTION; SUBSTANCE ABUSE;

ADMINISTRATION, CUTANEOUS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; COTININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NICOTINE; NICOTINIC AGONISTS; REPRODUCIBILITY OF RESULTS; SALIVA; SOLID PHASE EXTRACTION; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY;

EID: 79952108535     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/34.7.357     Document Type: Article

References (39)

1. E. Duncon. The copy of a letter written by E.D. Doctour of Physicke to a gentleman, by whom it was published. The former part conteineth rules for the preservation of health, and preventing of all diseases untill extreme olde age. Herein is inserted the authours opinion of tobacco [Letter]. Printed by Melchisedech Bradwood, London, U.K., 1606.
2. Centers for Disease Control and Prevention. Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses-United States, 2000-2004, 2008.
3. Substance Abuse and Mental Health Services Administration. Results from the 2007 National Survey on Drug Use and Health (Office of Applied Studies, NSDUH H-34, DHHS Publication No. SMA 08-4343), Rockville, MD, 2008.
4. N.L. Benowitz. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol. Rev. 18(2): 188-204 (1996).
5. Analytical Determination of Nicotine and Related Compounds and their Metabolites, 1st ed., J.W. Gorrod and P. Jacob, III, Eds. Elservier Science B.V., Amsterdam, The Netherlands, 1999.
6. D.W. Armstrong, X. Wang, J-T. Lee, and Y-S. Liu. Enantiomeric composition of nornicotine, anatabine, and anabasine in tobacco. Chirality 11(1): 82-84 (1999).
7. N.L. Benowitz and P. Jacob, III. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin. Pharmacol. Ther. 56(5): 483-493 (1994).
8. S. Zevin, P. Jacob, III, and N. Benowitz. Cotinine effects on nicotine metabolism. Clin. Pharmacol. Ther. 61: 649-653 (1997).
9. N.L. Benowitz and P. Jacob, III. Trans-3-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. Br. J. Clin. Pharmacol. 51: 53-59 (2001).
10. S. Shiffman. Light and intermittent smokers: background and perspective. Nicotine Tob. Res. 11: 122-125 (2009).
11. A. Rosengren, L. Wilhelmsen, and H. Wedel. Coronary heart disease, cancer and mortality in male middle-aged light smokers. J. Intern. Med. 231: 357-362 (1992).
12. National Cancer Institute. Cigars: Health effects and trends. Smoking and Tobacco Control. Monograph No. 9, 1998.
13. P.H. Whincup, J.A. Gilg, J.R. Emberson, M.J. Jarvis, C. Feyerabend, A. Bryant, M. Walker, and D.G. Cook. Passive smoking and risk of coronary heart disease and stroke: prospective study with cotinine measurement. Br. Med. J. 329(7459): 200-205 (2004).
14. I. Kim, W.D. Darwin, and M.A. Huestis. Simultaneous determination of nicotine, cotinine, norcotinine, and trans-3'-hydroxycotinine in human oral fluid using solid phase extraction and gas chromatography-mass spectrometry. J. Chromatogr. B 814: 233-240 (2005).
15. H.-S. Shin, J.-G. Kim, Y.-J. Shin, and S.-H. Jee. Sensitive and simple method for the determination of nicotine and cotinine in human urine, plasma and saliva by gas chromatography-mass spectrometry. J. Chromatogr. B 769(1): 177-183 (2002).
16. C.S. Parzynski, M. Jaszyna-Gasior, F.H. Franken, and E.T. Moolchan. Measuring nicotine intake among highly-dependent adolescent smokers: Comparability of saliva and plasma cotinine concentrations. Pharmacol. Biochem. Behav. 89(2): 145-149 (2008).
17. M.C. Bentley, M. Abrar, M. Kelk, J. Cook, and K. Phillips. Validation of an assay for the determination of cotinine and 3-hydroxy -cotinine in human saliva using automated solid-phase extraction and liquid chromatography with tandem mass spectrometric detection. J. Chromatogr. B 723: 185-194 (1999).
18. H. Kataoka, R. Inoue, K. Yagi, and K. Saito. Determination of nicotine, cotinine and related alkaloids in human urine and saliva by automated in-tube solid-phase microextraction coupled with liquid chromatography-mass spectrometry. J. Pharmaceut. Biomed. 49(1): 108-114 (2009).
19. D.M. Shakleya and M.A. Huestis. Optimization and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of nicotine, cotinine, trans-3-hydroxycotinine and norcotinine in human oral fluid. Anal. Bioanal. Chem. 395(7): 2349-2357 (2009).
20. S. Benkirane, A. Nicolas, M.M. Galteau, and G. Siest. Highly sensitive immunoassays for the determination of cotinine in serum and saliva. Comparison between RIA and an avidin-biotin ELISA. Eur. J. Clin. Chem. Clin. Biochem. 29(6): 405-410 (1991).
21. H.-W. Kuo, J.-S. Yang, and M.-C. Chiu. Determination of urinary and salivary cotinine using gas and liquid chromatography and enzyme-linked immunosorbent assay. J. Chromatogr. B 768: 297- 303 (2002).
22. V. Binnie, S. McHugh, L. Macpherson, B. Borland, K. Moir, and K. Malik. The validation of self-reported smoking status by analysing cotinine levels in stimulated and unstimulated saliva, serum and urine. Clin. Biochem. 10(5): 287-293 (2004).
23. R. Yoshida, M. Nakajima, Y. Watanabe, J-T. Kwon, and T. Yokoi. Genetic polymorphisms in human CYP 2A6 gene causing impaired nicotine metabolism. Br. J. Clin. Pharmacol. 54(5): 511-517 (2002).
24. M. Nakajima, T. Fukami, H. Yamanaka, E. Higashi, H. Sakai, R. Yoshida, J.T. Kwon, H.L. McLeod, and T. Yokoi. Comprehensive evaluation of variability in nicotine metabolism and CYP 2A6 polymorphic alleles in four ethnic populations. Clin. Pharmacol. Ther. 80(3): 282-297 (2006).
25. F. Patterson, N.L. Benowitz, P. Shields, V. Kaufmann, C. Jepson, P. Wileyto, S. Kucharski, and C. Lerman. Individual differences in nicotine intake per cigarette. Cancer Epidemiol. Biomarkers Prev. 12: 468-471 (2003).
26. E.I. Miller, H.-K. Norris, D.E. Rollins, S.T. Tiffany, and D.G. Wilkins. Simultaneous determination of nicotine, eight nicotine metabolites and two minor tobacco alkaloids in human plasma or urine by solid-phase extraction coupled to liquid chromatography-electrospray-tandem mass spectrometry. J. Chromatogr. B 878: 725- 737 (2010).
27. B.K. Matuszewski, M.L. Constanzer, and C.M. Chavez-Eng. Strategies for the assessment of matrix effect in quantitative bioanaly -tical methods based on HPLC-MS/MS. Anal. Chem. 75: 3019- 3030 (2003).
28. N.L. Benowitz. Biomarkers of environmental tobacco smoke exposure. Environ. Health Persp. 107: 349-355 (1999).
29. J.L. Pirkle, K.M. Flegal, J.T. Bernert, D.J. Brody, R.A. Etzel, and K.R. Maurer. Exposure of the US population to environmental tobacco smoke. The Third National Health and Nutrition Examination Survey, 1988 to 1991. J. Am. Med. Assoc. 275: 1233-1240 (1996).
30. Society of Forensic Toxicologists/American Academy of Forensic Sciences Laboratory Guidelines-2006. http://www.softtox.org/docs/Guidelines%202006%20Final.pdf.
31. N.L. Benowitz, J.T. Bernert, R.S. Caraballo, D.B. Holiday, and J. Wang. Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. Am. J. Epidemiol. 169(2): 236-248 (2009).
32. N.L. Benowitz. The use of biologic fluid samples in assessing tobacco smoke consumption. In Measurement in the Analysis and Treatment of Smoking Behavior, NIDA Research Monograph, No. 48, J. Grabowski and C. Bell, Eds. National Institute on Drug Abuse, Rockville, MD, 1983, pp 6-26.
33. J.-F. Etter, T.V. Duc, and T.V. Perneger. Saliva cotinine levels in smokers and nonsmokers. Am. J. Epidemiol. 151(3): 251-258 (2000).
34. A. Post, H. Gilijam, I. Rosendahl, L. Meurling, S. Bremberg, and M. Galanti. Validity of self-reports in a cohort of Swedish adolescent smokers and smokeless tobacco (snus) users. Tob. Control 14(2): 114-117 (2005).
35. G.K. Stookey, B.P. Katz, B.L. Olson, C.A. Drook, and S.J. Cohen. Evaluation of biochemical validation measures in determination of smoking status. J. Dent. Res. 66: 1597-1601 (1987).
36. J.E. Rose, E.D. Levin, and N. Benowitz. Saliva nicotine as an index of plasma levels in nicotine skin patch users. Ther. Drug Monit. 15(5): 431-435 (1993).
37. A.J. Jenkins, J.E. Henningfield, and E.J. Cone. Relationship between plasma and oral fluid nicotine concentrations in humans: a pilot study. Ther. Drug Monit. 27(3): 345-348 (2005).
38. M. Curvall, C.E. Elwin, E. Kazemi-Vala, C. Warholm. and C.R. Enzell. The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers. Eur. J. Clin. Pharmacol. 38(3): 281-287 (1990).
39. J. Nørregaard, P. Tønnesen, K. Simonsen, and U. Säwe. Long-term nicotine substitution after application of a 16-hour nicotine patch in smoking cessation. Eur. J. Clin. Pharmacol. 43(1): 57-60 (1992).